Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for the treatment of cancer and immune-related diseases. The company operates within the biotechnology and oncology drug development industries, with a primary emphasis on therapies that modulate the immune system through novel biological pathways rather than traditional checkpoint inhibition alone.
NextCure’s core business centers on the research and development of antibody-based therapeutics targeting immune signaling pathways. Its revenue to date has primarily been derived from collaboration and licensing arrangements rather than product sales, as the company does not yet have an approved commercial product. The company serves the global oncology market, targeting patients with solid tumors and hematologic malignancies, and positions itself through a science-driven approach focused on immune cell biology and tumor microenvironment modulation.
Founded in 2015, NextCure was established to translate discoveries from academic immunology research into clinical-stage drug candidates. The company became publicly traded in 2019, providing capital to advance its pipeline through early- and mid-stage clinical development. Since inception, its evolution has included pipeline reprioritization and portfolio optimization based on clinical trial outcomes.
Business Operations
NextCure’s operations are organized around its research and development programs, which constitute a single operating segment focused on immunomedicine discovery and clinical development. The company generates value by advancing proprietary drug candidates through preclinical research and clinical trials, with the goal of eventual regulatory approval or strategic partnering. Its lead and historical programs have included antibody therapeutics targeting immune receptors involved in myeloid cell and T-cell regulation.
The company conducts its research activities internally and through external collaborations with contract research organizations and clinical trial sites. NextCure controls a portfolio of intellectual property related to immune-modulating antibodies and platform technologies. While primarily U.S.-based, its clinical trials have included international sites. The company has engaged in strategic collaborations with larger pharmaceutical partners to support development and validation of certain programs.
Strategic Position & Investments
NextCure’s strategic direction emphasizes disciplined capital allocation, prioritization of high-potential immunology targets, and leveraging partnerships to offset development risk. Growth initiatives have focused on advancing selected clinical-stage assets while discontinuing or out-licensing programs that did not meet predefined efficacy or safety benchmarks.
The company has entered into collaboration and license agreements with established biopharmaceutical companies to support development and potential commercialization of certain candidates. These arrangements have included upfront payments, research funding, and milestone-based consideration. NextCure continues to invest in emerging immune-oncology targets, particularly those affecting antigen-presenting cells and immune suppression within the tumor microenvironment, while maintaining flexibility to adapt its pipeline based on clinical data.
Geographic Footprint
NextCure is headquartered in the United States, with its principal executive offices located in Maryland. Its core research and administrative operations are conducted domestically, supporting discovery, preclinical development, and corporate functions.
Although it does not maintain large-scale international facilities, the company has a global operational footprint through international clinical trials and collaborations. These activities extend its presence into Europe and other regions where oncology trial infrastructure supports patient recruitment and regulatory-compliant research.
Leadership & Governance
NextCure is led by executives with experience in biotechnology, immunology, and pharmaceutical development, guided by a strategy centered on scientific rigor and data-driven decision-making. The leadership team emphasizes translational science, careful clinical execution, and partnership-driven growth.
Key executives include:
- Michael Richman – President and Chief Executive Officer
- Margaret A. M. Foti – Chief Medical Officer
- Paul E. Levesque – Chief Financial Officer
- Philip M. Dorsch, Ph.D. – Chief Scientific Officer
The company’s governance framework includes an independent board of directors with expertise in drug development, finance, and corporate governance, supporting oversight of strategy, risk management, and shareholder interests.